Screener
Supernus Pharmaceuticals SUPN Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Municipal debt securities | 8,997 | — | 8,997 | — |
| U.S government agency securities | 992 | — | 992 | — |
| Other noncurrent assets | ||||
| Marketable securities - restricted (SERP) | 676 | 29 | 647 | — |
| Restricted cash | 1,450 | 1,450 | — | — |
| Total assets at fair value | $386,367 | $186,348 | $200,019 | — |
| Liabilities: | ||||
| Contingent consideration | $206 | — | — | $206 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's other non-current assets?
- Supernus Pharmaceuticals (SUPN) reported other non-current assets of $676K in Q1 2026.
- How has Supernus Pharmaceuticals's other non-current assets changed year-over-year?
- Supernus Pharmaceuticals's other non-current assets decreased by 97.7% year-over-year, from $29.22M to $676K.
- What is the long-term trend for Supernus Pharmaceuticals's other non-current assets?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other non-current assets has grown at a -56.1% compound annual growth rate (CAGR), from $43.25M to $705K.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Supernus Pharmaceuticals's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude